3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
131
Colonic Neoplasms
72
Rectal Neoplasms
61
Breast Neoplasms
61
Stomach Neoplasms
37
Pancreatic Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
27
Esophageal Neoplasms
24
Head and Neck Neoplasms
23
Neoplasm Metastasis
22
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Hepatocellular
16
Adenocarcinoma Of Esophagus
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
Neoplasms
11
Nasopharyngeal Carcinoma
11
Adenocarcinoma
7
Urinary Bladder Neoplasms
5
Keratosis, Actinic
5
Cholangiocarcinoma
5
Anus Neoplasms
5
Intestinal Neoplasms
4
Inflammatory Breast Neoplasms
4
Hepatoblastoma
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Biliary Tract Neoplasms
4
Laryngeal Neoplasms
3
Hypopharyngeal Neoplasms
3
HIV Infections
3
Interventions
pasireotide
2
Octreotide
2
Everolimus
2
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Leucovorin
1
Folfox protocol
1
Fluorouracil
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gastro-enteropancreatic neuroendocrine tumor
×
Fluorouracil
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled